Labcorp stock holds steady as investors look to next earnings signal

Published on 09/03/2026 at 22:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock is trading calmly ahead of the next earnings update, with recent reimbursement progress for its NASHnext test and solid precision medicine positioning shaping investor expectations.

3D-Rendering eines modernen Glas- und Stahl-Firmensitzes mit angrenzendem Laborgebäude — Architektur-Rendering eines gläsernen modernen Firmenhauptsitzes mit Laborflügel repräsentiert Labcorp, ISIN US50540R4092, aus der Diagnostikbranche, Illustration mit AI erstellt.

Labcorp (ISIN US50540R4092) stock is trading in a relatively stable range as of early September 3, 2026, with investors focusing on recent reimbursement progress for its NASHnext diagnostic test and the company’s role in the growing precision medicine market.

Market context and precision medicine position

The latest industry overview of precision medicine points to a global market that could reach USD 456.81 billion by 2035, implying a compound annual growth rate of 14.72 percent over the forecast period, according to a recent market report.

In that analysis, Labcorp is mentioned among key precision medicine players with an estimated revenue share of about 2 to 4 percent of the market, highlighting its meaningful but not dominant role alongside larger peers such as Qiagen and Exact Sciences.

Reimbursement progress for NASHnext test

A fresh update on liver disease diagnostics shows that Labcorp’s NASHnext test, based on GENFIT’s NIS4 technology, became eligible for reimbursement under the Clinical Laboratory Fee Schedule for patients meeting coverage criteria effective August 10, 2026, as noted in a recent announcement.

For Labcorp, the reimbursement decision is important because it turns NASHnext from a primarily out-of-pocket diagnostic into one that can be paid through established fee schedules, potentially lifting test volumes and related revenue over time compared with the pre-reimbursement phase when adoption was constrained by cost.

Go deeper

More background on Labcorp stock

For additional regulatory filings and company news around Labcorp stock, investors can use the themed overview and the company’s own investor relations materials.

Labcorp news and filings overview Investor Relations

Representative product: NASHnext diagnostic

One representative product in Labcorp’s portfolio is the NASHnext blood test, which is used to help identify patients with significant fibrosis due to nonalcoholic steatohepatitis and is now supported by reimbursement under the Clinical Laboratory Fee Schedule as of August 10, 2026, for eligible patients.

Stock perspective and investor takeaway

With precision medicine demand expanding and NASHnext gaining reimbursement, Labcorp stock is supported by structural growth drivers even as investors wait for the next earnings release to quantify how much incremental revenue these developments can bring relative to prior reporting periods.